Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexamethasone + docetaxel + ramucirumab
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of dexamethasone (a corticosteroid), docetaxel (a taxane chemotherapy), and ramucirumab (a VEGFR-2 inhibitor). This regimen is used primarily for the treatment of previously treated non-small cell lung cancer (NSCLC). Dexamethasone is administered as premedication to reduce adverse effects such as hypersensitivity reactions and fluid retention associated with docetaxel. The combination of docetaxel and ramucirumab has demonstrated improved overall survival and progression-free survival compared to docetaxel alone in patients with metastatic NSCLC whose disease has progressed during or after platinum-based chemotherapy.
- Other names
- DTX + RAM + DEX
02
Targets
GR (Glucocorticoid receptor)MicrotubuleVEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on dexamethasone + docetaxel + ramucirumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexamethasone + docetaxel + ramucirumab.